Endovascular Engineering (E2) is a medical device company founded in 2019 that has developed a nextgeneration mechanical thrombectomy system for the treatment of venous thromboembolism (VTE), pulmonary embolism (PE) and deep-vein thrombosis (DVT). The company has completed a successful pivotal clinical study (ENGULF) and received FDA 510(k) clearance for its Hēlo PE Thrombectomy System in December 2025, positioning the company for an initial US commercial launch.

E2’s Hēlo system is designed to enable efficient, singlepass clot removal through a lowprofile, catheterbased approach that combines aspiration with mechanical clot agitation and integrated blood return. The system is intended to address key limitations of firstgeneration thrombectomy devices, while improving safety, workflow simplicity, and
procedural predictability for clinicians treating acute PE.

In 2026, Gilde invested in Endovascular Engineering to support the US commercial launch of the Hēlo system, advance additional regulatory clearances, and accelerate market adoption in the rapidly growing VTE thrombectomy market, with the goal of improving outcomes for patients with lifethreatening thromboembolic disease.